HEPA_OUT_1 [2025-04-29 10:40:47 -0400] 6240 Bytes | 1653 tokens | Cum: 1653 tkns (20.66% of 8k)
==========================================================================

Alright, let’s light it up, because it's 10:40 AM on Tue Apr 29, 2025, and I'm charging into Hepion Pharmaceuticals (HEPA), popping from $0.2894 to $0.3353. Is this our star stock of the day, or just a quick blip on the radar? I've got the scoop—time to analyze!

--- COMPANY PROFILE ---
Company: Hepion Pharmaceuticals (HEPA)
IPO: 2014-02-07 (11 Years Ago)
Market Cap: $523,800
Shares Outstanding: 1,080,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.

Here’s a list of headlines for Hepion Pharmaceuticals:

Mar-14-25 12:15PM - Biotech Alert: Searches spiking for these stocks today
Mar-14-25 12:15PM 08:30AM - Hepion Pharmaceuticals Announces Reverse Stock Split
Jan-22-25 08:00AM - Hepion Pharmaceuticals Announces $9.0 Million Public Offering
Dec-11-24 08:00AM - Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.
Dec-05-24 08:30AM - Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson's Disease Study Group
Dec-02-24 08:00AM - Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
Nov-11-24 08:00AM - Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger
Sep-04-24 09:25AM - Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger
Jul-22-24 08:00AM - Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement
May-21-24 09:52PM - HEPA Stock Earnings: Hepion Pharmaceuticals Reported Results for Q1 2024
Apr-22-24 08:56AM - Why Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today?
Apr-19-24 04:30PM - Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b 'ASCEND-NASH' Trial
Apr-16-24 11:52PM - HEPA Stock Earnings: Hepion Pharmaceuticals Beats EPS for Q4 2023
Mar-06-24 08:30AM - Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell
Feb-16-24 08:00AM - Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds
Jan-03-24 05:15PM - Hepion Pharmaceuticals to Present at NASH-TAG 2024
Dec-07-23 08:00AM - Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes
Nov-28-23 04:15PM - Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit
Nov-13-23 04:05PM - Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease
Nov-10-23 08:50AM - Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 'ALTITUDE-NASH' Liver Function Trial of Rencofilstat
Oct-25-23 08:30AM - Hepion Pharmaceuticals' Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model
Sep-29-23 08:00AM - Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules

Prior AI Reports for HEPA:
1. 2025-04-02 – Score: 10 – Target: 0.7100 – Highs: 0.7000 / 0.5088 / 0.47
distressing-downward-trend-company-faces-severe-financial-headwinds
2. 2025-04-01 – Score: 20 – Target: 0.6000 – Highs: 0.9890 / 0.7000 / 0.51
company-faces-severe-decline-amidst-financial-distress

(Note: Highs = Same day / 2nd day / 3rd day)

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2024-12-11T13:00:00Z - Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.
B2 - 2024-12-02T13:00:00Z - Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
B3 - 2024-04-19T20:30:00Z - Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial
B4 - 2024-03-06T13:30:00Z - Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell
B5 - 2024-02-16T13:00:00Z - Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds
B6 - 2024-01-03T22:15:00Z - Hepion Pharmaceuticals to Present at NASH-TAG 2024

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Hepion Pharmaceuticals (HEPA).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

HEPA_OUT_3 [2025-04-29 10:40:48 -0400] 840 Bytes | 221 tokens | Cum: 1876 tkns (23.45% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/12/11/2995333/0/en/Hepion-Pharmaceuticals-Inc-Announces-Termination-of-Merger-Agreement-with-Pharma-Two-B-Ltd.htmlHepion Pharmaceuticals has terminated its merger agreement with Pharma Two B Ltd. and has withdrawn proposals for a special stockholder meeting. The company is continuing efforts to provide value from its drug candidate rencofilstat to shareholders.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

HEPA_OUT_5 [2025-04-29 10:40:48 -0400] 775 Bytes | 216 tokens | Cum: 2094 tkns (26.17% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-09T17:06:21Z - 12 Health Care Stocks Moving In Wednesday's Intraday Session - Aardvark Therapeutics (NASDAQ:AARD), ...
A2 - 2025-04-09T12:07:29Z - 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Adverum Biotechnologies (NASDAQ:ADV...
A3 - 2025-04-01T17:05:47Z - 12 Health Care Stocks Moving In Tuesday's Intraday Session - bioAffinity Technologies (NASDAQ:BIAF),...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

HEPA_OUT_7 [2025-04-29 10:40:49 -0400] 1181 Bytes | 357 tokens | Cum: 2453 tkns (30.66% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**12 Health Care Stocks Moving In Wednesday's Intraday Session - Aardvark Therapeutics (NASDAQ:AARD), Hepion Pharmaceuticals (NASDAQ:HEPA)**Date: 2025-04-09Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/04/44718421/12-health-care-stocks-moving-in-wednesdays-intraday-sessionGainers Venus Concept VERO stock moved upwards by 179.4% to $8.16 during Wednesday's regular session. The company's market cap stands at $5.3 million. Phio Pharma PHIO shares moved upwards by 67.33% to $1.69. The market value of their outstanding shares is at $8.0 million. SCWorx WORX shares rose 42.58% to $1.14. The company's market cap stands at $2.3 million. Hepion Pharmaceuticals HEPA stock moved upwards by 26.68% to $0.52. Lexeo Therapeutics LXEO stock moved upwards by 19.73% to $2.18. The company's market cap stands at $72.3 million. Vo

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

HEPA_OUT_9 [2025-04-29 10:40:50 -0400] 1181 Bytes | 353 tokens | Cum: 2808 tkns (35.10% of 8k)
==========================================================================

Showing A1 (chunk 2 of 3): litionRX VNRX stock rose 19.49% to $0.55. The market value of their outstanding shares is at $54.0 million. Losers Vincerx Pharma VINC stock fell 55.2% to $0.24 during Wednesday's regular session. Neogen NEOG stock fell 38.85% to $4.3. The market value of their outstanding shares is at $933.9 million. The company's, Q3 earnings came out today. Salarius Pharmaceuticals SLRX stock fell 37.21% to $0.51. Aardvark Therapeutics AARD stock fell 31.01% to $5.03. The market value of their outstanding shares is at $107.5 million. LogicMark LGMK stock decreased by 29.37% to $0.01. ZyVersa Therapeutics ZVSA shares declined by 22.05% to $0.99. The company's market cap stands at $2.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

AARDAardvark Therapeutics Inc$5.02-31.1%Stock Score Locked:

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

HEPA_OUT_11 [2025-04-29 10:40:51 -0400] 1002 Bytes | 312 tokens | Cum: 3122 tkns (39.02% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-08 10-K ITEM 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

You should read the following discussion and analysis of our financial condition and results of operations together with our CONS financial statements and the related notes app...

S2 - 2024-11-14 10-Q PART IFIN INFO

Item 1. Condensed Cons Fin Stmnts

HEPION PHARMACEUTICALS, INC. & SUBSIDIARIES

COND CONS BAL SHEETS

(Unaudited)

September 30, 2024 December 31, 2023 Assets Curr assets: Cash $ 1,497,106 $ 14,785,880 Pr...

S3 - 2024-11-14 10-Q PART IFIN INFO

Item 1. Condensed Cons Fin Stmnts

HEPION PHARMACEUTICALS, INC. & SUBSIDIARIES

COND CONS BAL SHEETS

(Unaudited)

September 30, 2024 December 31, 2023 Assets Curr assets: Cash $ 1,497,106 $ 14,785,880 Pr...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

HEPA_OUT_13 [2025-04-29 10:40:52 -0400] 1181 Bytes | 243 tokens | Cum: 3367 tkns (42.09% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
ITEM 7. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes appearing elsewhere in this Annual Report. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled Risk Factors included elsewhere in this Annual Report. All amounts in this report are in U.S. dollars, unless otherwise noted.

Overview

We are a biopharmaceutical company headquartered in Mor

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

HEPA_OUT_15 [2025-04-29 10:40:53 -0400] 1181 Bytes | 274 tokens | Cum: 3643 tkns (45.54% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): ristown, New Jersey, that was previously focused on the development of drug therapy for treatment of chronic liver diseases. Our cyclophilin inhibitor, rencofilstat (formerly CRV431), was being developed to offer benefits to address multiple complex pathologies related to the progression of liver disease.

We were developing rencofilstat as our lead molecule. Rencofilstat is a compound that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulate protein folding, in addition to other activities. Many closely related isoforms of cyclophilins exist in humans. Cyclophilins A, B, and D are the best characterized cyclophilin isoforms. Inhibition of cyclophilins has been shown in scientific literature to have therapeutic effects in a variety of experimental models, including liver disease models.

We have completed a number of Phase 1 and Pha

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

HEPA_OUT_17 [2025-04-29 10:40:54 -0400] 1181 Bytes | 284 tokens | Cum: 3929 tkns (49.11% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): se 2 clinical trials. In May 2023, we announced that our Phase 2a study (ALTITUDE-NASH) met its primary endpoint by demonstrating improved liver function and was well tolerated after four months of treatment with once daily oral rencofilstat administered to NASH subjects with stage 3 or greater fibrosis. All additional secondary efficacy and safety endpoints were also met. These observations provide further evidence that builds on previous findings from a shorter 28-day Phase 2a (AMBITION) trial. Taken together, the AMBITION and ALTITUDE-NASH trials reinforced rencofilstats direct antifibrotic mode of action and increase our confidence level that we anticipated observing fibrosis reductions in our 12-month Phase 2b (ASCEND-NASH) clinical trial.

##TABLE_START 42 ##TABLE_END

##TABLE_START ##TABLE_END

In June 2023, we announced that the Data and Safety Monitoring Board (DSMB) met to rev

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

HEPA_OUT_19 [2025-04-29 10:40:55 -0400] 1181 Bytes | 262 tokens | Cum: 4193 tkns (52.41% of 8k)
==========================================================================

Showing S1 (chunk 4 of 6): iew the current data for the ASCEND-NASH 2b study and issued a study may proceed without modification clearance. This, the first planned DSMB meeting, occurred on schedule, and all labs, electrocardiograms, adverse events, and protocol deviations were reviewed, focusing on any potential safety signals from the placebo-controlled trial.

In December 2023, the board of directors approved a strategic restructuring plan to preserve capital by reducing operating costs. We incurred a one-time restructuring charge of approximately $0.7 million in the fourth quarter of 2023. Additionally, we initiated a process to explore a range of strategic and financing alternatives focused on maximizing stockholder value within the current financial environment and NASH drug development landscape.

On April 19, 2024, we announced that we have begun wind-down activities in our ASCEND- NASH clinical trial. W

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

HEPA_OUT_21 [2025-04-29 10:40:55 -0400] 1181 Bytes | 266 tokens | Cum: 4461 tkns (55.76% of 8k)
==========================================================================

Showing S1 (chunk 5 of 6): e did not have access to sufficient funding to complete the study, as designed. The wind-down activities were implemented to halt further clinical activities other than those which would allow for an orderly and patient safety manner that would meet the minimum FDA requirements for safely closing a clinical trial. All clinical trial activities were completed and the trial was closed in August 2024.

On July 19, 2024, we along with Pharma Two B Ltd., a company organized under the laws of the State of Israel ( Parent ), and Pearl Merger Sub, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent ( Merger Sub ), entered into an Agreement and Plan of Merger (the Merger Agreement ), pursuant to which, among other things, on the terms and subject to the conditions set forth therein, Merger Sub will merge with and into us (the Merger ), pursuant to which we would surviv

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

HEPA_OUT_23 [2025-04-29 10:40:56 -0400] 790 Bytes | 205 tokens | Cum: 4668 tkns (58.35% of 8k)
==========================================================================

Showing S1 (chunk 6 of 6): e the Merger as an indirect wholly owned subsidiary of Parent.

Concurrently with the Merger, on July 19, 2024, we entered into a Securities Purchase Agreement (the SPA ) with certain purchasers pursuant to which we sold an aggregate of $2.9 million in principal amount of our Original Issue Discount Senior Unsecured Nonconvertible Notes (the Notes ). The Notes are due on the earlier of: (i) December 31, 2024, (ii) the date of the closing of the Merger, (iii) the date that the Merger is terminated p...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

HEPA_OUT_25 [2025-04-29 10:41:03 -0400] 5907 Bytes | 1556 tokens | Cum: 6226 tkns (77.83% of 8k)
==========================================================================

This is our set of metrics for Hepion Pharmaceuticals.
Please analyze the numbers.

+-------------------+-----------------------+------------------------+-----------------------+
| Volume: 321,341 | Perf Month: -34.38% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+-------------------+-----------------------+------------------------+-----------------------+
| Avg Volume: 3.89M | Perf Quarter: -97.17% | Short Float: 5.93% | ROE: -487.03% |
+-------------------+-----------------------+------------------------+-----------------------+
| Rel Volume: 0.45 | Index: - | Short Ratio: 0.17 | ROI: - |
+-------------------+-----------------------+------------------------+-----------------------+
| RSI (14): 22.59 | Market Cap: 3.46M | Short Interest: 0.65M | Sales Surprise: - |
+-------------------+-----------------------+------------------------+-----------------------+
| ATR (14): 0.22 | Shs Outstand: 10.98M | Beta: 1.91 | EPS Surprise: -17.54% |
+-------------------+-----------------------+------------------------+-----------------------+
| SMA20: -16.15% | Shs Float: 10.92M | Sales Q/Q: - | P/E: - |
+-------------------+-----------------------+------------------------+-----------------------+
| SMA50: -87.41% | Inst Own: 0.28% | Sales past 5Y: 0.00% | Earnings: - |
+-------------------+-----------------------+------------------------+-----------------------+
| SMA200: -98.66% | Insider Own: 0.48% | Employees: - | |
+-------------------+-----------------------+------------------------+-----------------------+
| Perf Week: 12.46% | Insider Trans: 0.00% | Debt/Eq: - | |
+-------------------+-----------------------+------------------------+-----------------------+

The next section covers any insider trading by Hepion Pharmaceuticals officers or majority shareholders (if available).

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -22704594.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.32845
Average Volume: 9295119.0
30-Day High: 0.4878
30-Day Low: 0.27

[Detailed Financials: Q3 2024]
- Total Assets: $3,715,098.00
- Total Liabilities: $4,121,783.00
- Total Equity: $-406,685.00
- Current Assets: $3,530,292.00
- Current Liabilities: $2,715,964.00

[Income Statement: Q3 2024]
- Revenue: $0.00
- Net Income: $-4,865,948.00
- Gross Profit: N/A
- Operating Income: $-4,458,259.00
- Earnings Per Share (EPS): -0.72

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $14,495,592.00

[Detailed Financials: Q2 2024]
- Total Assets: $6,010,164.00
- Total Liabilities: $2,448,334.00
- Total Equity: $3,561,830.00
- Current Assets: $5,482,409.00
- Current Liabilities: $975,634.00

[Income Statement: Q2 2024]
- Revenue: $0.00
- Net Income: $-3,925,212.00
- Gross Profit: N/A
- Operating Income: $-8,503,848.00
- Earnings Per Share (EPS): -0.68

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $-14,433,832.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Hepion Pharmaceuticals (HEPA).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Hepion Pharmaceuticals.

2) MARKET_SCORE[]
This conversation was initiated because HEPA is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for HEPA.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, HEPA could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect HEPA to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Hepion Pharmaceuticals.

11) ETHICAL_RATING[]
Rate Hepion Pharmaceuticals’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Hepion Pharmaceuticals.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

HEPA_IN_27 [2025-04-29 10:41:03 -0400] 126 Bytes | 29 tokens | Cum: 6450 tkns (80.62% of 8k)
==========================================================================

====================================
[2025-04-29 10:41:03] # Analysis Completed
Elapsed Time: 17.84 seconds